Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Aurobindo Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹1,426.10
High
₹1,463.90
Price Summary
| Previous Close | ₹1,462.00 |
|---|---|
| Day's Range | ₹1,426.10 - ₹1,463.90 |
| Open | ₹1,431.00 |
| 52 Week Range | ₹1,016.10 - ₹1,459.50 |
| Volume | 5,65,120 |
| Market Cap | ₹0.08 |
| Previous Close | ₹1,464.30 |
|---|---|
| Day's Range | ₹1,428.05 - ₹1,468.00 |
| Open | ₹1,428.05 |
| 52 Week Range | ₹1,017.00 - ₹1,459.75 |
| Volume | 38,776 |
| Market Cap | ₹0.08 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 8,262.05 |
|---|---|
| Market Cap (₹ in Mn) | 0.08 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 23.79 |
| TTM EPS (₹) | 60.04 |
| P/E Ratio | 19.32 |
| Book Value(₹) | 2.31 |
| PAT Margin (%) | 5.48 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 14.39 |
| Trade Value ( ₹ in Lacs) | 567.80 |
|---|---|
| Market Cap (₹ in Mn) | 0.08 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 23.79 |
| TTM EPS (₹) | 60.04 |
| P/E Ratio | 19.32 |
| Book Value(₹) | 2.31 |
| PAT Margin (%) | 5.48 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 14.39 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 79785.2 | 106456.4 |
| Expenses | N/A | N/A |
| PBT | 11998.5 | 24029.2 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 8455.7 | 19541.4 |
About Aurobindo Pharma Ltd.
| Founded | 1986 |
|---|---|
| Managing Director | K Nityananda Reddy |
| NSE Symbol | AUROPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,36,858.91 | 1,831.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,76,617.57 | 6,658.35 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,44,717.58 | 4,320.00 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,11,737.93 | 7,765.00 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,07,721.85 | 1,344.30 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,07,143.97 | 2,398.00 | 1,836.80 - 1,836.80 |
| Dr. Reddy's Laboratories Ltd. | 1,06,080.73 | 1,286.20 | 1,129.40 - 1,129.40 |
| Max Healthcare Institute Ltd. | 97,300.05 | 1,008.35 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 95,803.01 | 2,314.55 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 91,753.45 | 925.45 | 835.50 - 835.50 |
No Records Found
Latest News
Aurobindo Pharma informs about updates
Aurobindo Pharma informs about press release
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Industrial Development Area, Chemical Zone, Pashamylaram Village, Patancheru Mandal, Sangareddy District, 502307, Telangana from December 01 to December 12, 2025. At the end of the inspection, a ‘Form 483’ was issued with 03 observations. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (VAI) and this inspection is now ‘closed’.
The above information is a part of company’s filings submitted to BSE.
Aurobindo Pharma informs about disclosure
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from December 08 to December 17, 2025. At the end of the inspection, a ‘Form 483’ was issued with 05 observations. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (VAI) and this inspection is now ‘closed’.
The above information is a part of company’s filings submitted to BSE.
Aurobindo Pharma submits analyst meet intimation
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Aurobindo Pharma Ltd. is ₹1,462.00 as of 2026-05-06.
The market capitalisation of Aurobindo Pharma Ltd. is ₹82,950.09 as of 2026-05-05.
The 1-year return of Aurobindo Pharma Ltd. is 33.90% as of 2026-05-06.
The P/E ratio of Aurobindo Pharma Ltd. is 19.32 as of 2026-05-06.
The 52-week high and low of Aurobindo Pharma Ltd. are ₹1,459.50 and ₹1,016.10, respectively, as of 2026-05-06.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
